|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. (e) Acquired
in-process research and development costs
In July 2006, Elan and Archemix Corp. entered into a multi-year,
multi-product alliance focused on the discovery, development and
commercialization of aptamer therapeutics to treat autoimmune
diseases. As a result of the alliance, Elan paid Archemix an
upfront payment of $7.0 million. In addition, in September
2006, Elan and Transition announced an exclusive, worldwide
collaboration agreement for the joint development and
commercialization of ELND005 for the treatment of
Alzheimer’s disease. Elan incurred a charge related to the
license fee of $15.0 million, of which $7.5 million
was paid to Transition in 2006 and the rest in 2007. For
additional information, refer to Item 4.B. “Business
Overview,” which describes our R&D programs in detail.
Table of Contents
This excerpt taken from the ELN 20-F filed Feb 28, 2008. (D) Acquired
in-process research and development costs
In July 2006, Elan and Archemix entered into a multi-year,
multi-product alliance focused on the discovery, development and
commercialization of aptamer therapeutics to treat autoimmune
diseases. As a result of the alliance, Elan paid Archemix an
upfront payment of $7.0 million. In addition, in September
2006, Elan and Transition announced an exclusive, worldwide
collaboration agreement for the joint development and
commercialization of ELND005, for the treatment of
Alzheimer’s disease. Elan incurred a charge related to the
license fee of $15.0 million, of which $7.5 million
was paid to Transition in 2006 and the rest in 2007. For
additional information, please refer to Item 4.B.
“Business Overview,” which describes our R&D
programs in detail.
This excerpt taken from the ELN 20-F filed Feb 28, 2007. (A) Acquired
in-process research and development costs
In July 2006, Elan and Archemix Corp. (Archemix) entered into a
multi-year, multi-product alliance focused on the discovery
development and commercialization of aptamer therapeutics to
treat autoimmune diseases. As a result of the alliance, Elan
paid Archemix an upfront payment of $7.0 million. In
addition, in September 2006, Elan and Transition Therapeutics,
Inc. (Transition), announced an exclusive, worldwide
collaboration agreement for the
Table of Contents
Elan
Corporation, plc
NOTES TO
THE CONSOLIDATED
FINANCIAL STATEMENTS — (Continued)
joint development and commercialization of AZD-103, for the
treatment of Alzheimer’s disease. Elan incurred a charge
related to the license fee of $15.0 million, of which
$7.5 million was paid to Transition in the fourth quarter
of 2006 and the remaining balance is due to be paid in 2007.
| EXCERPTS ON THIS PAGE:
|
| |||||||
